Seres Therapeutics Inc (MCRB) - Total Assets
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) holds total assets worth $117.62 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Seres Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Seres Therapeutics Inc - Total Assets Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Seres Therapeutics Inc (MCRB) shareholders funds for net asset value and shareholders' equity analysis.
Seres Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Seres Therapeutics Inc's total assets of $117.62 Million consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.1% |
| Accounts Receivable | $360.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Seres Therapeutics Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seres Therapeutics Inc's current assets represent 35.7% of total assets in 2025, a decrease from 95.5% in 2012.
- Cash Position: Cash and equivalents constituted 33.1% of total assets in 2025, down from 95.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Seres Therapeutics Inc Competitors by Total Assets
Key competitors of Seres Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Seres Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.65 | 2.11 | 4.00 |
| Quick Ratio | 1.65 | 2.11 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.49 Million | $34.76 Million | $168.39 Million |
Seres Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Seres Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | $138.19 Million |
| Market Capitalization | $46.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seres Therapeutics Inc's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Seres Therapeutics Inc's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Seres Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Seres Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $138.19 Million | -1.16% |
| 2024-12-31 | $139.81 Million | -61.01% |
| 2023-12-31 | $358.60 Million | +2.81% |
| 2022-12-31 | $348.78 Million | -1.71% |
| 2021-12-31 | $354.86 Million | +3.48% |
| 2020-12-31 | $342.94 Million | +158.94% |
| 2019-12-31 | $132.44 Million | +9.93% |
| 2018-12-31 | $120.47 Million | -36.43% |
| 2017-12-31 | $189.52 Million | -30.49% |
| 2016-12-31 | $272.65 Million | +25.70% |
| 2015-12-31 | $216.90 Million | +84.84% |
| 2014-12-31 | $117.34 Million | +5422.12% |
| 2013-12-31 | $2.12 Million | -67.50% |
| 2012-12-31 | $6.54 Million | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more